ACHP Statement on “Most-Favored-Nation” Rx Pricing Executive Order
ACHP released a statement on the most-favored-nation prescription drug …
05/12/2025
Anticompetitive practices within the pharmaceutical industry, coupled with outdated patent laws that inhibit more affordable biosimilars and generics, have resulted in skyrocketing drug costs for all Americans – but especially seniors and those with chronic conditions. ACHP advocates for sensible policies such as price transparency to rein in sky-high costs so that patients can afford the medications they need.
A Lifeline for Rare Diseases
Learn MoreACHP released a statement on the most-favored-nation prescription drug …
05/12/2025
ACHP calls on Congress to curb direct-to-consumer (DTC) drug ad …
04/10/2025
ACHP President and CEO Ceci Connolly released a statement in …
04/04/2025
ACHP sent a letter to CMS Administrator, Dr. Oz, with …
04/04/2025
ACHP President and CEO Ceci Connolly coauthored an op-ed examining …
04/10/2024
Transparency in the drug supply chain is desperately needed to …
03/24/2025
When people with diabetes follow their prescribed medical regimens, they …
11/10/2023
Morgan Health CEO Dan Mendelson joins the Healthy Dialogue podcast …
09/13/2022
ACHP applauds the Senate for passing the Inflation Reduction Act, …
08/07/2022
The Alliance of Community Health Plans has sent Congressional Leaders …
04/25/2022
ACHP calls on Congress to curb direct-to-consumer (DTC) drug ad …
04/10/2025
ACHP urges the Trump Administration to pursue commonsense health care deregulation that eliminates waste, cuts costs, and empowers local health plans to deliver high-quality, affordable care.
05/16/2025
Texas-based ACHP member plan Baylor Scott & White Health Plan recognized what we all know: diabetes diagnoses are increasing and becoming more expensive to manage. When faced with this unfortunately …
05/15/2025
ACHP released a statement in response to the House Energy and Commerce's budget reconciliation markup.
05/14/2025
ACHP released a statement on the most-favored-nation prescription drug pricing executive order.
05/12/2025